Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis

Detalhes bibliográficos
Autor(a) principal: Lara, Vanessa Soares
Data de Publicação: 2023
Outros Autores: Silva, Rafaela Alves da, Ferrari, Tatiane Ponteado, Santos, Carlos Ferreira dos, Oliveira, Sandra Helena Penha de [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
DOI: 10.1089/adt.2023.013
Texto Completo: http://dx.doi.org/10.1089/adt.2023.013
http://hdl.handle.net/11449/245642
Resumo: Candidosis is one of the most frequent opportunistic infections and exhibits variable clinical presentations, including oral localized forms. Drugs affecting the renin-angiotensin system targets inhibit secreted aspartic proteases from Candida albicans. The objective of the study was to evaluate whether losartan has antimicrobial action against C. albicans biofilms. Biofilms were treated with losartan or aliskiren (for comparison) for 24 h. Metabolic activity of viable cells and growth inhibition of C. albicans biofilms were assessed using XTT [2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide] and colony-forming unit assays, respectively. In addition, the cytotoxicity of the drugs on human cells was evaluated using the AlamarBlue assay. Both drugs decreased fungal viability at all concentrations. In addition, all concentrations of losartan inhibited the growth of C. albicans biofilm, ranging from 47% to 88.5%, whereas aliskiren showed inhibition from 1 to 10 mg/mL, which ranged from 16% to 97.6%. Furthermore, at certain concentrations, these drugs maintained the viability of human cells. Losartan and aliskiren have fungistatic and fungicidal action against C. albicans biofilms and are compatible with human cells. Therefore, these antihypertensive drugs can be repurposed to interfere with the metabolism and development of Candida biofilms, which are widely associated with clinical forms of candidosis, including oral localized forms such as denture stomatitis.
id UNSP_aa111be71cbb03c5351b10ba73ba8230
oai_identifier_str oai:repositorio.unesp.br:11449/245642
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosisaliskirendenture stomatitislosartandrug repositioningCandida albicansCandidosis is one of the most frequent opportunistic infections and exhibits variable clinical presentations, including oral localized forms. Drugs affecting the renin-angiotensin system targets inhibit secreted aspartic proteases from Candida albicans. The objective of the study was to evaluate whether losartan has antimicrobial action against C. albicans biofilms. Biofilms were treated with losartan or aliskiren (for comparison) for 24 h. Metabolic activity of viable cells and growth inhibition of C. albicans biofilms were assessed using XTT [2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide] and colony-forming unit assays, respectively. In addition, the cytotoxicity of the drugs on human cells was evaluated using the AlamarBlue assay. Both drugs decreased fungal viability at all concentrations. In addition, all concentrations of losartan inhibited the growth of C. albicans biofilm, ranging from 47% to 88.5%, whereas aliskiren showed inhibition from 1 to 10 mg/mL, which ranged from 16% to 97.6%. Furthermore, at certain concentrations, these drugs maintained the viability of human cells. Losartan and aliskiren have fungistatic and fungicidal action against C. albicans biofilms and are compatible with human cells. Therefore, these antihypertensive drugs can be repurposed to interfere with the metabolism and development of Candida biofilms, which are widely associated with clinical forms of candidosis, including oral localized forms such as denture stomatitis.Univ Sao Paulo, Bauru Sch Dent, Dept Surg Stomatol Pathol & Radiol, Bauru, BrazilUniv Sao Paulo, Integrated Res Ctr, Bauru Sch Dent, Bauru, BrazilUniv Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Bauru, BrazilSao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, Immunopharmacol Lab, Aracatuba, BrazilUniv Sao Paulo, Bauru Sch Dent, Dept Surg Stomatol Pathol & Radiol, Alameda Dr Otavio Pinheiro Brisolo 9-75, BR-17012901 Bauru, SP, BrazilSao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, Immunopharmacol Lab, Aracatuba, BrazilMary Ann Liebert, IncUniversidade de São Paulo (USP)Universidade Estadual Paulista (UNESP)Lara, Vanessa SoaresSilva, Rafaela Alves daFerrari, Tatiane PonteadoSantos, Carlos Ferreira dosOliveira, Sandra Helena Penha de [UNESP]2023-07-29T12:00:51Z2023-07-29T12:00:51Z2023-05-25info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article9http://dx.doi.org/10.1089/adt.2023.013Assay and Drug Development Technologies. New Rochelle: Mary Ann Liebert, Inc, 9 p., 2023.1540-658Xhttp://hdl.handle.net/11449/24564210.1089/adt.2023.013WOS:000993051500001Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAssay And Drug Development Technologiesinfo:eu-repo/semantics/openAccess2024-09-19T14:02:46Zoai:repositorio.unesp.br:11449/245642Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-09-19T14:02:46Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
title Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
spellingShingle Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
Lara, Vanessa Soares
aliskiren
denture stomatitis
losartan
drug repositioning
Candida albicans
Lara, Vanessa Soares
aliskiren
denture stomatitis
losartan
drug repositioning
Candida albicans
title_short Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
title_full Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
title_fullStr Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
title_full_unstemmed Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
title_sort Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
author Lara, Vanessa Soares
author_facet Lara, Vanessa Soares
Lara, Vanessa Soares
Silva, Rafaela Alves da
Ferrari, Tatiane Ponteado
Santos, Carlos Ferreira dos
Oliveira, Sandra Helena Penha de [UNESP]
Silva, Rafaela Alves da
Ferrari, Tatiane Ponteado
Santos, Carlos Ferreira dos
Oliveira, Sandra Helena Penha de [UNESP]
author_role author
author2 Silva, Rafaela Alves da
Ferrari, Tatiane Ponteado
Santos, Carlos Ferreira dos
Oliveira, Sandra Helena Penha de [UNESP]
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universidade de São Paulo (USP)
Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv Lara, Vanessa Soares
Silva, Rafaela Alves da
Ferrari, Tatiane Ponteado
Santos, Carlos Ferreira dos
Oliveira, Sandra Helena Penha de [UNESP]
dc.subject.por.fl_str_mv aliskiren
denture stomatitis
losartan
drug repositioning
Candida albicans
topic aliskiren
denture stomatitis
losartan
drug repositioning
Candida albicans
description Candidosis is one of the most frequent opportunistic infections and exhibits variable clinical presentations, including oral localized forms. Drugs affecting the renin-angiotensin system targets inhibit secreted aspartic proteases from Candida albicans. The objective of the study was to evaluate whether losartan has antimicrobial action against C. albicans biofilms. Biofilms were treated with losartan or aliskiren (for comparison) for 24 h. Metabolic activity of viable cells and growth inhibition of C. albicans biofilms were assessed using XTT [2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide] and colony-forming unit assays, respectively. In addition, the cytotoxicity of the drugs on human cells was evaluated using the AlamarBlue assay. Both drugs decreased fungal viability at all concentrations. In addition, all concentrations of losartan inhibited the growth of C. albicans biofilm, ranging from 47% to 88.5%, whereas aliskiren showed inhibition from 1 to 10 mg/mL, which ranged from 16% to 97.6%. Furthermore, at certain concentrations, these drugs maintained the viability of human cells. Losartan and aliskiren have fungistatic and fungicidal action against C. albicans biofilms and are compatible with human cells. Therefore, these antihypertensive drugs can be repurposed to interfere with the metabolism and development of Candida biofilms, which are widely associated with clinical forms of candidosis, including oral localized forms such as denture stomatitis.
publishDate 2023
dc.date.none.fl_str_mv 2023-07-29T12:00:51Z
2023-07-29T12:00:51Z
2023-05-25
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1089/adt.2023.013
Assay and Drug Development Technologies. New Rochelle: Mary Ann Liebert, Inc, 9 p., 2023.
1540-658X
http://hdl.handle.net/11449/245642
10.1089/adt.2023.013
WOS:000993051500001
url http://dx.doi.org/10.1089/adt.2023.013
http://hdl.handle.net/11449/245642
identifier_str_mv Assay and Drug Development Technologies. New Rochelle: Mary Ann Liebert, Inc, 9 p., 2023.
1540-658X
10.1089/adt.2023.013
WOS:000993051500001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Assay And Drug Development Technologies
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9
dc.publisher.none.fl_str_mv Mary Ann Liebert, Inc
publisher.none.fl_str_mv Mary Ann Liebert, Inc
dc.source.none.fl_str_mv Web of Science
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv repositoriounesp@unesp.br
_version_ 1822183860018872320
dc.identifier.doi.none.fl_str_mv 10.1089/adt.2023.013